Sheth R D, Goulden K J, Ronen G M
Department of Neurology, West Virginia University, Health Science Center, Morgantown 26506-9180, USA.
Clin Neuropharmacol. 1994 Aug;17(4):332-7. doi: 10.1097/00002826-199408000-00004.
Seven of 63 children (11%) treated with clobazam (CLB) for refractory epilepsy developed a severe behavior disorder. This disorder was characterized by aggressive agitation, self injurious behavior, insomnia, and incessant motor activity occurring between 10 and 55 days after initiation of drug therapy. The affected children were relatively young (mean age 6.4 years) and developmentally disabled (four were autistic and two had isolated mental retardation). The disorder occurred with a short latency after initiation of therapy and at a relatively low dosage of CLB. Serum levels of other coadministered antiepileptic drugs were unchanged by the administration of CLB. One child was taking CLB monotherapy. This behavioral deterioration required the discontinuation of CLB, after which patients returned to their previous behavior within 3 weeks. After > 3 years of follow-up all children continue to require multiple antiepileptic drugs but have not had a recurrence of this aggressive agitation. The mechanism of the behavioral change is unclear.
63名接受氯巴占（CLB）治疗难治性癫痫的儿童中有7名（11%）出现了严重的行为障碍。这种障碍的特征是攻击性躁动、自我伤害行为、失眠以及在药物治疗开始后10至55天出现的持续运动活动。受影响的儿童相对年幼（平均年龄6.4岁）且有发育障碍（4名患有自闭症，2名有孤立性智力障碍）。该障碍在治疗开始后潜伏期较短时出现，且CLB剂量相对较低。同时服用的其他抗癫痫药物的血清水平不受CLB给药的影响。1名儿童接受CLB单药治疗。这种行为恶化需要停用CLB，停药后患者在3周内恢复到之前的行为状态。经过3年多的随访，所有儿童仍继续需要多种抗癫痫药物，但这种攻击性躁动未再复发。行为改变的机制尚不清楚。
